Video Source: YouTube, Hindustan Times
Johnson & Johnson said it is still in talks with the Government of India on the COVID-19 vaccine after the Indian drug company announced the drug company. Withdrawal of application for expedited approval of field trials..
Development will take place two months after India says so. Abandon the requirements for a post-approval bridging trial Changes have been made to established foreign vaccines to help speed up the deployment of national immunizations and fight off further waves of infection.
On Monday, a J & J spokesman said Hindustan Times, “The Drugs Controller General of India (DCGI) recently ordered that it is no longer necessary to conduct bridging clinical trials of the COVID-19 vaccine in India, so Johnson & Johnson withdrew its application to conduct these trials. . ”
A spokeswoman added that the company is looking forward to “continuous discussions” with the government and “continues to look for ways to accelerate availability” of the one-shot vaccine in India.
Junior Health Minister Bharati Pravin Pawar said last week that the government had formed a team with vaccine makers Pfizer-BioNTech, Moderna and J & J.Discuss and address a variety of issues, including compensation issues.. ”
So far four vaccines have been granted Emergency use authorization in India — AstraZeneca plc’s Covishield, Bharat Biotech’s Covaxin, Russian Gamaleya Institute’s Sputnik V, Moderna Inc’s COVID-19 vaccine.
that’s all 7.6% of Indian adults are fully vaccinated 27% have been vaccinated against the coronavirus at least once.
The government still declares that it aims to vaccinate the entire adult population of 1.08 billion. By the end of 2021However, the drive has been hampered by slow paces, underdose, and vaccine hesitation.
sauce: Equity news